Immunocore Holdings plc (IMCR)

Immunocore Holdings plc at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Immunocore Holdings plc (IMCR) is a Biotechnology company based in GB with a market capitalization of $1.5B. Revenue grew 20.0% year-over-year and free cash flow was negative at -$11.2M. This page tracks IMCR's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

GB · 493 employees · IPO Feb 5, 2021

Valuation

Valuation & price

$29.47as of May 26, 2026· -26.7% vs 52w high

P/E ratio

Latest-FY diluted EPS

3.85

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$40.22$34.06$27.91Jul 25Dec 25Jul 26
$27.7952-week range$40.22
Loading valuation history…

Fundamentals

Key fundamentals

$1.5B

Market cap

20.0%

Revenue growth (YoY)

97.9%

Gross margin

-$11.2M

Free cash flow (USD)

-$820.6M

Net debt

Net cash position

0.7%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20162025

$20.2M$297.6M

Free cash flow by year

20162025

-$52.9M-$11.2M

Gross margin by year

20212025

100.0%97.9%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 6, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventMay 27, 2026Filing

    Annual General Meeting Results

  • Quarterly reportMay 6, 2026Filing

    10-Q Filed

  • 8-K eventMay 6, 2026Filing

    Earnings Release

Questions

Frequently asked questions

What is Immunocore Holdings plc's market cap?

Immunocore Holdings plc (IMCR) has a market capitalization of $1.5B.

What is IMCR's P/E ratio?

A meaningful P/E ratio is not available for IMCR — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is IMCR's price-to-book (P/B) ratio?

IMCR trades at 3.85 times book value per share.

Are insiders buying IMCR stock?

SEC Form 4 filings show no open-market insider buys at Immunocore Holdings plc in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.